Increasing capabilities in real-world evidence (RWE) development, a larger focus on patient centricity, and the limitations of evidence derived from randomized controlled trials (RCTs) have all led to a greater focus on the use of pragmatic studies to support health care decisions and market access. Pragmatic studies aim to quantify the risks, benefits and costs of an intervention in routine clinical practice, often helping to inform how a treatment may be applied by clinicians outside of the clinical trial environment. Considered quasi-experimental, pragmatic trials invoke randomization, typically involve a broader range of patients, study sites, and outcomes, including a greater emphasis on quality of life and long term functional impact, than the typical RCT.